Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185

Sunitinib (SU11248) is an orally bioavailable inhibitor that affects the receptor tyrosine kinases involved in tumour proliferation and angiogenesis, including vascular endothelial growth factor (vegf) receptors 1, 2, 3, and platelet-derived growth factor receptors alpha (pdgfra) and beta (pdgfrb)....

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Main Authors: Buckstein, R., Meyer, R.M., Seymour, L., Biagi, J., MacKay, H., Laurie, S., Eisenhauer, E.
Formáid: Artigo
Teanga:Inglês
Foilsithe: Multimed Inc. 2007
Ábhair:
Canadian Centre Activities
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC1948864/
https://ncbi.nlm.nih.gov/pubmed/17710208
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla